In the IONESCO trial, 50 patients with early-stage NSCLC were included (IB ≥4 cm – IIIA, non N2). The patients were treated with 3 courses of durvalumab (750 mg, day 1, 15, 29). Surgery was scheduled between day 2 and 14 after the last infusion [1]. In the PRINCEPS trial, 30 patients were included (I > 2cm - IIIA, non N2). Patients received 1 injection of atezolizumab (1,200 mg). Surgery was scheduled in week 4 after the atezolizumab treatment [2].
In IONESCO, 46 patients received neoadjuvant treatment of whom 43 went into surgery without any delay. Overall, 41/46 patients in IONESCO (89.1%) had complete surgical resection (R0); 4 (8.7%) had partial radiological response (RECIST 1.1), and 36 (78.3%) stable disease; 8 patients (18.6%) had major pathological response (<10% residual viable tumour cells). After one year, 89.1% of the patients in IONESCO were still alive; 78.2% had not relapsed.
In PRINCEPS, all patients had their surgery as scheduled. In total, 29/30 (97%) patients had complete surgical resection; 2 (7%) patients showed partial radiological response (RECIST 1.1), and 27 (93%) had stable disease; 4 (14%) patients had major pathological response (<10% residual viable tumour cells) and 12 patients (41%) had pathological response (<50% viable tumour cells). There was no correlation between radiological and pathological response. However, there was a correlation between pathological response and PD-L1 expression at baseline.
- Wislez M, et al. Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO). ESMO 2020 Virtual Meeting, abstract 1214O.
- Besse B, et al. SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial. ESMO 2020 Virtual Meeting, abstract 1215O.
Posted on
Previous Article
« No advantage of post-operative radiotherapy in patients with stage IIIA N2 NSCLC Next Article
Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer? »
« No advantage of post-operative radiotherapy in patients with stage IIIA N2 NSCLC Next Article
Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer? »
Table of Contents: ESMO 2020
Featured articles
COVID-19 and Cancer
Breast Cancer
Gastrointestinal Cancers
Lung Cancer
Melanoma
Genitourinary Cancers
Bladder cancer risk and early detection
Gynaecological Cancers
Basic Science
Related Articles
November 25, 2020
Adjuvant immune checkpoint inhibition after complete resection
November 25, 2020
New treatment option for patients with mCRPC
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com